IGMS IGM Biosciences, Inc.

IGM Biosciences, Inc. operates as a biotechnology company which develops antibodies for the treatment of cancer. It offers IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The company was founded in 2010 and is headquartered in Mountain View, CA.

$65.90  -0.21 (-0.32%)
As of 05/12/2021 16:00:00 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/28/2019
Outstanding shares:  25,594,748
Average volume:  188,779
Market cap:   $1,680,551,154
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    449585108
ISIN:        US4495851085
Sedol:      BKS3SM8

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   4.76
PS ratio:   0.00
Return on equity:   -26.82%
Net income %:   0.00%